This study aimed to evaluate the influence of a waiting interval of ! 8 weeks between the end of preoperative neoadjuvant chemoradiotherapy (nCRT) and surgery on the outcomes of patients with locally advanced rectal cancer. We conducted a comprehensive literature review of retrospective and prospective studies from PubMed, Embase, and Cochrane Library databases to investigate the length of the preoperative nCRTesurgery waiting interval and outcomes in patients with locally advanced rectal cancer. The primary outcome measure was pathologic complete response (pCR) rate. Secondary outcome measures included overall survival, disease-free survival, operative time, and the incidence of local recurrence, postoperative complications, anastomotic leakage, and sphincter-preserving surgery. Standardized mean differences and risk ratios were calculated. Thirteen studies involving 19,652 patients were included. The meta-analysis demonstrated that pCR was significantly increased in patients with locally advanced rectal cancer and a waiting interval of ! 8 weeks between preoperative nCRT and surgery compared to a waiting interval of < 8 weeks, or a waiting interval of > 8 weeks compared to 8 weeks (risk ratio ¼ 1.25; 95% confidence interval, 1.16-1.35; P < .0001). There were no significant differences in overall survival, disease-free survival, operative time, or incidence of local recurrence, postoperative complications, or sphincter-preserving surgery. This study revealed that performing surgery after a waiting interval of ! 8 weeks after the end of preoperative nCRT is safe and efficacious for patients with locally advanced rectal cancer, significantly improving pCR without increasing operative time or incidence of postoperative complications, compared to a waiting interval of 8 weeks.
Introduction
In the Western world, rectal cancer is among the most common cancers and the second leading cause of cancer-related death. 1, 2 In patients with localized rectal tumors treated with surgical resection, 5-year and 10-year survival is estimated at 60% and 50%, respectively. 3 Total mesorectal excision (TME) is the standard surgical procedure for rectal cancer. TME results in reduced rates of local recurrence (LR) compared to conventional surgery. 4, 5 Apart from surgery, neoadjuvant chemoradiotherapy (nCRT) is used to reduce the risk of LR in resectable rectal cancer, downsize the tumor, and facilitate subsequent successful R0 resection or sphincter-preserving surgery in locally advanced rectal cancer. 6, 7 At present, multimodal and multidisciplinary treatment, including preoperative nCRT and TME, are considered the standard treatment for patients with locally advanced rectal cancer, defined as T3-T4 with positive lymph nodes. [8] [9] [10] Typically, nCRT constitutes of a course of a 5-fluorouracilebased or oxaliplatin-based chemotherapy (FOLFOX [folinic acid, fluorouracil, and oxaliplatin] or XELOX [capecitabine and oxaliplatin]) regimen and external beam radiotherapy with a total dose of 45 to 50. 4 Gy delivered in 25 daily fractions to pelvic lymph nodes and the tumor. This approach is associated with improved overall survival (OS) and reduced incidence of LR. 11, 12 To date, there is no consensus on the length of waiting interval between the end of preoperative nCRT and surgery. The Lyons R90-01 prospective randomized trial revealed that tumor downstaging was significantly increased in patients with a 6-to 8-week waiting interval between preoperative radiotherapy and rectal surgery, compared to a 2-week waiting interval. This established 6 to 8 weeks as a widely accepted radiationesurgery waiting interval. 13 However, it remains unclear whether a longer waiting interval before surgery results in further tumor downstaging or a higher rate of pathologic complete response (pCR). pCR, defined as the complete absence of tumor cells in the resected specimen and lymph nodes (ypT0N0), 14 or no intact cancer cells found in the resected specimen regardless of the presence of mucin lakes, 15 is associated with improved local control, OS, and disease-free survival (DFS). 16, 17 One meta-analysis reported that a waiting interval longer than 6 to 8 weeks between the end of preoperative nCRT and rectal surgery increases pCR. 18 Some studies have shown that a waiting interval of ! 8 weeks is beneficial, 8, 19 while other reports indicated that a waiting interval beyond 8 weeks is not advantageous. 15, 20, 21 This systematic review and meta-analysis aimed to evaluate the influence of a waiting interval of ! 8 weeks between the end of preoperative nCRT and surgery on pCR, OS, DFS, operative time, and the incidence of LR, postoperative complications, anastomotic leakage, and sphincterpreserving surgery in patients with locally advanced rectal cancer.
Methods
This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. 22 
Data Collection
Two review authors (D.D. and Z.S.) independently searched the PubMed, Embase, and Cochrane Library databases from inception to February 2017 using the following keywords: "interval" or "time" or "timing" and "neoadjuvant chemoradiation" or "preoperative chemoradiation" and "rectal cancer" and "surgery." The search strategy is summarized in Figure 1 . This search was limited to publications in the English language.
Inclusion and Exclusion Criteria
Inclusion criteria were as follows: studies of patients with locally advanced rectal cancer who underwent nCRT before surgery that compared the pCR rate according to the length of the waiting interval between preoperative nCRT and surgery (eg, < 6, 6-8, < 8, ! 8, 9-10, or > 10 weeks).
Exclusion criteria were as follows: studies that did not report pCR; studies with sample size of < 10 patients; and commentaries, editorials, or conference abstracts.
Study Selection
Two review authors (D.D. and Z.S.) independently examined the titles and abstracts to select eligible studies. The full text of potentially relevant studies was retrieved. Two review authors (D.D. and Z.S.) independently examined the full text records to determine which studies met the inclusion criteria. Disagreements on the study selection were resolved by discussion and consensus.
Data Extraction
Two review authors (D.D. and Z.S.) independently extracted data from eligible studies including details that described the study population, interventions, and outcome measures.
The primary outcome measure was pCR rate. Secondary outcome measures included OS, DFS, operative time, and the incidence of LR, postoperative complications, anastomotic leakage, and sphincter-preserving surgery.
Disagreements on data extraction were resolved by discussion and consensus.
Assessment of Quality of Evidence in Included Studies
The Newcastle-Ottawa scale (NOS) and Jadad score were used to assess the quality of the observational comparative studies and randomized controlled trials included in this review, respectively.
The NOS assessed for potential selection bias, the comparability of cases and controls or cohorts, and the ascertainment of outcome (caseecontrol studies) or exposure (cohort studies). Points (also termed "stars") are awarded and summed. For the purpose of this analysis, studies with ! 5 stars were considered high quality and were included into the study. Studies with < 4 stars were considered low quality and were excluded from the study.
The Jadad scale is a 5-point scale in which a score of 2 indicates poor-quality evidence and a score of ! 3 indicates highquality evidence. Therefore, trials with a score of 3 to 5 were considered to be of high methodologic quality.
Publication bias was assessed by Begg's funnel plot and Begg's rank correlation test of asymmetry. Publication bias was thought to be present when the continuity-corrected Pr > jzj value was 0.1.
Disagreements on assessment of quality of evidence in the included studies were resolved by discussion and consensus. Abbreviation: PRISMA ¼ Preferred Reporting Items for Systematic Reviews and Meta-analyses.
Statistical Analysis
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Surgery After Chemoradiotherapy in Rectal Cancer The waiting intervals between the end of preoperative nCRT and surgery reported in the included studies were not uniform. Therefore, outcomes were pooled to create 2 groups: 1 group compared waiting intervals 8 and > 8 weeks, and 1 group compared waiting intervals < 8 and ! 8 weeks.
Standardized mean differences with 95% confidence intervals (CIs) were calculated for continuous variables, and risk ratios (RRs) with 95% CIs were calculated for dichotomous variables. A random-effects model was used to pool studies with significant heterogeneity, as determined by the chi-square test (P .10) and the inconsistency index (I 2 ! 50%).
Sensitivity analysis, excluding one study at a time, was performed to confirm that our results were robust.
Results
The search identified 1914 articles. Titles and abstracts were screened, and 30 studies were considered potentially eligible for inclusion. Full-text articles were retrieved, and 13 studies were found to be eligible for inclusion according to our criteria for considering studies in this review 8, 20, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] ( Figure 1 ).
The characteristics of the included studies are shown in Table 1 . The 13 eligible studies included one phase 2 nonrandomized trial 
Outcomes
Primary Outcome. pCR in patients with locally advanced rectal cancer undergoing preoperative nCRT was described in all 13 studies (n ¼ 19,652). 8, 20, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The meta-analysis demonstrated that pCR was significantly increased in patients with locally advanced rectal cancer and a waiting interval of ! 8 weeks compared to patients with a waiting interval of < 8 weeks (RR ¼ 1.24; 95% CI, 1.14-1.35; P < .0001) or > 8 weeks compared to 8 weeks (RR ¼ 1.36; 95% CI, 1.06-1.76; P ¼ .016) (overall, RR ¼ 1.25; 95% CI, 1.16-1.35; P < .0001). There was no evidence of significant heterogeneity among studies (P ¼ .347, I 2 ¼ 9.8%; Figure 2 ).We excluded each single trial to perform sensitivity analyses, and the outcome demonstrated that pCR was significantly increased in patients with locally advanced rectal cancer and a waiting interval of ! 8 weeks (Table 2) .
Secondary Outcomes. OS, DFS, operative time, and the incidence of LR, postoperative complications, anastomotic leakage, and sphincter-preserving surgery in patients with locally advanced rectal cancer undergoing preoperative nCRT were described in several studies pooled to compare waiting intervals of ! 8 and < 8 weeks or > 8 and 8 weeks between the end of preoperative nCRT and surgery. The meta-analysis demonstrated no significant differences in OS (n ¼ 579; RR ¼ 0.98; 95% CI, 0.91-1.06; P ¼ .623; heterogeneity: P ¼ .139, I
2 ¼ 42.4%; Figure 3) to 0.32; P ¼ .103; heterogeneity: P ¼ .265, I 2 ¼ 24.3%; Figure 5 ), [25] [26] [27] 29 or the incidence of LR (n ¼ 781; RR ¼ 0.92; 95% CI, 0.61-1.37; P ¼ .671; heterogeneity: P ¼ .014, I 2 ¼ 65.1%; Figure 6 ), 8, 23, 26, 27, 29, 33 postoperative complications (n ¼ 2077; RR ¼ 0.95; 95% CI, 0.83-1.09; P ¼ .476; heterogeneity: P ¼ .251, I 2 ¼ 25.6%; Figure 7) , 25, 26, [29] [30] [31] anastomotic leakage (n ¼ 745; RR ¼ 0.89; 95% CI, 0.49-1.63; P ¼ .714; heterogeneity: P ¼ .518, I 2 ¼ 0%; Figure 8 ), 8, 20, 24, 26, 27, 29, 33 or sphincter-preserving surgery (n ¼ 1016; RR ¼ 0.99; 95% CI, 0.91-1.07; P ¼ .743; heterogeneity: P ¼ .861, I 2 ¼ 0%; Figure 9 ) 8, 23, [25] [26] [27] 29, [31] [32] [33] in patients with locally advanced rectal cancer and a waiting interval of ! 8 weeks compared to those with a waiting interval of < 8 weeks, or > 8 weeks compared to 8 weeks.
Assessment of Study Quality
The level of evidence for each study was high according to the NOS 8, 20, [23] [24] [25] [26] [27] [28] [30] [31] [32] [33] and Jadad quality score. 29 For publication bias, the shape of the funnel plot revealed no obvious asymmetry (P ¼ .617) for trials that investigated pCR (Figure 10 ), and Begg's test was not significant (z ¼ 0.67 [continuity corrected] Pr > jzj ¼ 0.502 [continuity corrected]).
Other Waiting Intervals
Twelve trials included data on other waiting intervals between the end of preoperative nCRT and surgery, including a 7-week waiting interval 9, 14, [34] [35] [36] (n ¼ 5), a 6-week interval 37 (n ¼ 1), a 60-day interval 38 (n ¼ 1), a 44-day interval 39 (n ¼ 1), a 12-week interval 40 (n ¼ 1), a 5-to 6-week versus a > 6-week interval 41 (n ¼ 1), a 2-week interval versus a 6-to 8-week interval 13 (n ¼ 1), and a 2-week versus a 6-to 8-week interval 42 (n ¼ 1) (Table 3 ).
Pooled analysis showed that an interval of > 7 weeks between the end of preoperative nCRT and surgery can significantly increase pCR in patients with locally advanced rectal cancer 14, [34] [35] [36] (n ¼ 1012; RR ¼ 1.51; 95% CI, 1.20-1.89; P < .001; heterogeneity: P ¼ .189, I 2 ¼ 37.3%; Figure 11 ).
Sensitivity Analysis
To confirm that our results for pCR are robust, we performed a sensitivity analysis, excluding one study at a time. Results showed that the overall findings of the meta-analysis were not affected by the inclusion or exclusion of any one particular study (Table 2) .
Discussion
The results of the present study indicate that a waiting interval of ! 8 weeks between preoperative nCRT and surgery in patients with locally advanced rectal cancer is safe and efficacious, resulting in improved pCR but no increase in operative time or incidence of postoperative complications compared to shorter waiting intervals. In accordance with our findings, Bitterman et al 43 and Martin et al 44 found that the length of the waiting interval between preoperative nCRT and surgery was an independent predictor of pCR in patients with rectal cancer. Furthermore, Kalady et al 19 demonstrated that a longer waiting time between preoperative neoadjuvant therapy and surgery was the single most important determinant of pCR. pCR after nCRT is an important prognostic factor in rectal cancer because it is associated with improved long-term OS and DFS as well as decreased incidence of LR and distant metastases. 16, 17, 44 Furthermore, tumor regression facilitates surgical resection. A previous meta-analysis of 5 randomized controlled trials demonstrated that preoperative nCRT versus preoperative radiotherapy alone significantly increased pCR (P < .0001), but this did not determine the optimal waiting interval between nCRT and surgery. 46 The Lyon R90-01 trial revealed that a waiting interval of 6 to 8 weeks between preoperative radiation and rectal surgery increased tumor downstaging compared to a waiting interval of 2 weeks (26% vs. 10.3%; P ¼ .0054). However, there was no significant difference in pCR (14% vs. 7%; P ¼ .166) or the incidence of postoperative complications, sphincter-preserving surgery or LR, 13 or 5-year survival. 47 A retrospective study conducted by Calvo et al 37 reported that a waiting interval of > 6 weeks versus < 6 weeks between preoperative nCRT and surgery in locally advanced rectal cancer had no effect on the incidence or severity of postoperative complications. However, pCR (12.1% vs. 8.8%; P ¼ .34), 5-year OS (70.4% vs. 55.9%; P ¼ .014), 5-year DFS, and 5-year local control were not significantly improved. 37 One study suggested that a waiting interval of ! 12 weeks between preoperative nCRT and surgery was feasible. Notably, patients who receive pelvic radiation may experience pelvic edema or pelvic fibrosis. Therefore, the waiting interval between preoperative nCRT and surgery should be optimized to minimize the complexity of surgery and postoperative complications. Our study revealed no significant difference in operative time or the incidence of postoperative complications in patients who underwent a waiting interval of ! 8 weeks between preoperative nCRT and surgery compared to patients who underwent a waiting interval of 8 weeks. Garcia-Aguilar et al 25 reported no difference in surgical difficulty and the incidence of postoperative complications in patients who underwent TME at 6 or 11 weeks after nCRT, and the postoperative length of hospital stay was shorter in patients who delayed surgery. Any surgical approach to rectal cancer should be curative (R0) and should ensure that the distal margin is negative. The operative approach usually includes abdominoperineal resection and sphincter-preserving surgery. Evidence suggests that preoperative nCRT can increase the rate of sphincter-preserving surgery in locally advanced rectal cancer. 48 Our study found no difference in the incidence of sphincter-preserving surgery in patients who underwent a waiting interval of ! 8 weeks versus < 8 weeks or a waiting interval of > 8 weeks compared to 8 weeks. This systematic review and meta-analysis indicated that delaying surgery by ! 8 weeks after the end of nCRT in rectal cancer patients is safe and efficacious. Some clinicians are concerned that longer waiting intervals are associated with pelvic fibrosis; this makes surgery challenging and may affect long-term prognosis. Conversely, the current study showed no significant difference in operative time or postoperative complications, such as anastomotic leakage, in patients with a waiting interval of ! 8 weeks compared to those with a waiting interval of < 8 weeks, or > 8 weeks compared to 8 weeks, and no obvious differences in prognosis (OS, DFS). Interestingly, our pooled analysis also showed that an interval of > 7 weeks between the end of preoperative nCRT and surgery can significantly increase pCR in patients with locally advanced rectal cancer. These data indicate that further studies are required to find the optimal waiting interval in this patient population.
Included studies were of high methodologic quality, and there was no evidence of heterogeneity. However, our analyses were associated with several limitations. First, we only included one randomized trial. Thus, the correlation of pCR with surgical delay could not be adjusted in a multivariate analysis with other clinicopathologic variables. Second, outcomes such as DFS, OS, and LR could not be meaningfully assessed as a result of the small sample size. Third, our analyses only considered a waiting interval of ! 8 weeks between preoperative nCRT and surgery and did not identify an upper limit. In a retrospective study, Probst et al 28 reported that pCR peaked at a waiting interval between 10 and 11 weeks. Sloothaak et al 30 concluded that delaying surgery for 10 to 11 weeks after nCRT provided the greatest opportunity for achieving pCR. Kwak et al 49 reported that tumor response was maximal when the waiting interval between preoperative nCRT and surgery was 7 to 10 weeks. Last, the preoperative nCRT regimens used in the included studies were varied, and this may affect the length of the nCRTesurgery waiting interval and outcomes. Large prospective trials, such as the trial investigating a short course of preoperative chemoradiotherapy followed by a delayed operation for locally advanced rectal cancer (ClinicalTrials.gov NCT01129700), are required to directly evaluate the effect of a waiting interval of ! 8 weeks between preoperative nCRT and surgery in patients with locally advanced rectal cancer on operative time, postoperative complications, and patient outcomes.
In conclusion, this study showed that performing surgery after a waiting interval of ! 8 weeks after the end of preoperative nCRT is safe and efficacious compared to a waiting interval of < 8 weeks, resulting in significantly improved pCR and no increase in operative time or incidence of postoperative complications.
